Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
106-120 of 4420 results
Lonza agrees to acquire Capsugel for $5.5bn
By PBR Staff Writer
Swiss pharmaceutical firm Lonza has agreed to acquire US drug capsules manufacturer Capsugel from Kohlberg Kravis Roberts (KKR) for $5.5bn in cash.
Drug Research > Drug Discovery & Development > News
Third Rock launches Goldfinch Bio for kidney disease work
Third Rock Ventures has launched Goldfinch Bio, a company focused on the discovery and development of precision therapies for patients with kidney disease.
Drug Research > Drug Discovery & Development > News
Bayer, Versant Ventures invest $225m in new stem cell therapy company
By PBR Staff Writer
Bayer and health care investment firm Versant Ventures are investing $225m in a new stem cell therapy company, BlueRock Therapeutics.
Drug Research > Drug Discovery & Development > News
Forge Therapeutics, Evotec establish superbug alliance
Forge Therapeutics has partnered with Evotec to advance its novel Gram-negative antibiotic program targeting ‘LpxC’ to treat bacterial infections including those caused by drug resistant superbugs.
Drug Research > Drug Discovery & Development > News
Bicycle, AstraZeneca enter into potential $1bn multitarget collaboration
By PBR Staff Writer
Bicycle Therapeutics and AstraZeneca have agreed a $1bn multi-target collaboration across respiratory, cardiovascular and metabolic diseases.
Drug Research > Drug Discovery & Development > News
Evotec, Merck sign deals to partner on target discovery technologies
Evotec and Merck have signed agreements to collaborate on target discovery technologies.
Drug Research > Drug Discovery & Development > News
OxThera raises EUR32m to complete Oxabact development to treat primary hyperoxaluria
Swedish privately-held biopharmaceutical firm OxThera has raised EUR32m to complete development of Oxabact for the treatment of primary hyperoxaluria.
Drug Research > Drug Discovery & Development > News
Ergomed acquires PharmInvent
Pharmaceutical services and drug development firm Ergomed has acquired European PharmInvent Services s.r.o. (PharmInvent), a European pharmacovigilance and regulatory services business.
Drug Research > Drug Discovery & Development > News
UK biopharmaceutical firm Kymab secures $100m of funding
By PBR Staff Writer
UK-based biopharmaceutical firm Kymab has secured $100m of funding to advance its pipeline of therapeutic human monoclonal antibodies.
Drug Research > Drug Discovery & Development > News
WuXi Biologics, Prima sign non-binding MOU for biologics development
WuXi Biologics, a WuXi AppTec group company, and Prima Biomed have signed a non-binding MOU to form a strategic biologics development and manufacturing partnership.
Drug Research > Drug Discovery & Development > News
Allergan acquires Chase Pharmaceuticals
Allergan has acquired Chase Pharmaceuticals, a clinical-stage biopharmaceutical firm engaged in the development of improved treatments for neurodegenerative disorders including Alzheimer's disease (AD).
Drug Research > Drug Discovery & Development > News
FDA scientists develop new mouse model for Zika studies
Scientists at the US Food and Drug Administration (FDA) have developed a new mouse model which may help in exploring the potential activity of Zika virus vaccines and therapeutics.
Drug Research > Drug Discovery & Development > News
PharmAkea, Celgene expand fibrotic disease therapy partnership
PharmAkea's three-year-old collaboration with Celgene to develop novel small-molecule therapies targeting fibrotic diseases has been extended nine months.
Drug Research > Drug Discovery & Development > News
TNK Therapeutics enters into binding term sheet to buy Virttu Biologics
Sorrento Therapeutics' subsidiary TNK Therapeutics has entered into a binding term sheet to acquire Virttu Biologics.
Drug Research > Drug Discovery & Development > News
Selexis, OSE partner to advance immunotherapies development for cancer diseases
Selexis and OSE Immunotherapeutics have signed two service agreements to advance development of immunotherapies for cancer and autoimmune diseases.
Drug Research > Drug Discovery & Development > News
106-120 of 4420 results